“Eamonn Hobbs brings to Morris Innovative a wealth of industry contacts and successful operating experience ,” said John Morris, CEO of Morris. “Given Eamonn’s 30-plus years of identifying and commercializing a wide variety of innovative medical technologies, we are looking forward to his contributions as Morris moves into the commercial phase of our development.”
“When Morris Innovative invited me to join the board, I saw an opportunity to help the company advance the treatment of cardiovascular disease through their unique vascular closure products, CombiClose and the very recently introduced ControlClose”
Mr. Hobbs brings to Morris Innovative more than 30 years of leadership experience in a number of medical technology industry segments including interventional radiology, oncology, interventional cardiology, surgery, gastroenterology and medical device/pharmaceutical combination products. After graduating from the University of Massachusetts-
In addition to Morris Innovative, Mr. Hobbs also is Chairman of the Board of Marvao Medical, Inc., and is a member of the Board of Directors of Antares Pharmaceuticals (NASDAQ: ATRS); Harmonic Medical, Inc. the MDMA and the Glens Falls (NY) Hospital.
About Morris Innovative
Morris Innovative is a medical device company based in Bloomington, Indiana that is commercializing a patented device for use by interventional cardiologists, radiologists, and vascular surgeons. Our products, CombiClose and the very recently introduced ControlClose provide vascular closure for patients undergoing treatment for cardiovascular and peripheral disease. With over 30,000 sold in the US, CombiClose is the only combination working sheath/closure device. The very recently introduced ControlClose is a more standard exchange closure system. Both of the devices incorporate an introducer sheath with a pre-mounted biologic material (Small Intestinal Submucosa, “SIS”) which is used to seal and promote rapid healing of the common femoral artery following a catheterization procedure. CombiClose and ControlClose also deliver unsurpassed safety by allowing the clinican to completely be in control of the closure process. The product received Premarket Approval (PMA) from the FDA in August 2007 and a subsequent approval in July 2008 due to multiple design enhancements. For more information, log on to www.morrisinnovative.com